Work

A phase II single-arm study of the FGFR inhibitor pemigatinib in patients with metastatic colorectal cancer (mCRC) harboring FGF/FGFR alterations.

Year: 2023

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2023.41.4_suppl.139

Authors: Kristen Keon Ciombor, Tyler J. Zemla, Joleen M. Hubbard, Jingquan Jia, Olumide B. Gbolahan, Andrea Sousa, Luke Wilson, Blake Waechter, Fang-Shu Ou, Andrew B. Nixon, Tanios S. Bekaii-Saab

Institutions: Vanderbilt University Medical Center, Mayo Clinic, Duke Medical Center, Emory University, Mayo Clinic in Arizona, Mayo Clinic Comprehensive Cancer Center (Arizona)

Language: English

Topic: Colorectal Cancer Treatments and Studies

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Incyte

OpenAlex ID: W4317877668

Cites:

Cited by: 14

Related to: 10